Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
The impact of systemic therapy on survival of patients with metastatic melanoma is uncertain. This retrospective analysis aimed to compare the response rates and survival of patients without prior therapy with cisplatin, vinblastine, dacarbazine and interleukin (IL)-2 who were treated with biochemotherapy (containing these drugs plus interferon-alpha) with those of patients who received combination chemotherapy with and without interferon-alpha (chemotherapy +/- IFN). Records for 616 chemo-naive patients with unresectable metastatic melanoma who were treated on eight Phase II/III clinical trials between 1987 and 2001 were combined and reviewed The database included patients with melanoma of the skin (497 cases), unknown primary melanoma (83 cases), mucosal melanoma (21 cases), and uveal melanoma (15 cases). Two hundred sixty-four patients received biochemotherapy, and 352 received chemotherapy +/- IFN. The overall response rate (complete and partial) of patients treated with biochemotherapy was 52% (138/264) compared with 35% (122/352) among patients treated with chemotherapy +/- IFN regimens. The median survival times for patients in the biochemotherapy and chemotherapy +/- IFN groups were 12.2 mo (95% CI: 10.9, 13.5) and 9.1 mo (95% CI: 8.1, 10.4), respectively (p < 0.0001). Five-year overall survival rates of patients treated with biochemotherapy and chemotherapy +/- IFN were 17% and 7% (p = 0.0004), respectively. Ten-year overall survival rates were 15% and 5% (p = 0.0001), respectively. We conclude from these studies that patients benefited more from biochemotherapy than other regimens.
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. abedikia@mdanderson.org
Agop Y
AY
Bedikian
Marcella M
MM
Johnson
Carla L
CL
Warneke
Susan
S
McIntyre
Nicholas
N
Papadopoulos
Wen-Jen
WJ
Hwu
Kevin
K
Kim
Patrick
P
Hwu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D016208:Databases, Factual; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality*; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D015996:Survival Rate; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D014747:Vinblastine / Q000008:administration & dosage
C508594:IL2 protein, human; D016898:Interferon-alpha; D007376:Interleukin-2; D014747:Vinblastine; D003606:Dacarbazine; D002945:Cisplatin